Show Notes
Dr. Aaron S. Zelikovich discusses the phase 3 NIMBLE trial of cemdisiran, an siRNA targeting complement component 5, for the treatment of generalized myasthenia gravis. Show citation: Vu T, Habib AA, Jacob S, et al. Efficacy and safety of cemdisiran siRNA in myasthenia gravis (NIMBLE): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet. 2026;407(10540):1712-1725. doi:10.1016/S0140-6736(26)00690-2
More from Neurology Minute
Dr. Katie Krulisky and Dr. Kelsey Smith discuss the impact of menopause on women with epilepsy, including therapeutics and clinical management during midlife. Show citation: Smith KM, Faubion SS, Vadlamudi L, et al. The Menopause Transition and Epilepsy: A Focus on Therapeutics. Neurol Clin Pract. 2026;16(5):e200650. doi:10.1212/CPJ.0000000000200650
Dr. Katie Krulisky and Dr. Kelsey Smith discuss the impact of menopause on women with epilepsy, including therapeutics and clinical management during midlife. Show citation: Smith KM, Faubion SS, Vadlamudi L, et al. The Menopause Transition and Epilepsy: A Focus on Therapeutics. Neurol Clin Pract. 2026;16(5):e200650. doi:10.1212/CPJ.0000000000200650
Dr. Casey Kozak discusses a new scoring system for MOGAD identification. Show citation: Vilaseca A, Filippatou AG, Said Y, et al. TRUE-MOGAD Score: A Novel Scoring System to Identify MOGAD Among Positive MOG-IgG Test Results. Neurol Neuroimmunol Neuroinflamm. 2026;13(5):e200617. doi:10.1212/NXI.0000000000200617
Dr. Hailey Katulski discusses limb compression therapy and chemotherapy-induced peripheral neuropathy in women with gynecologic cancers. Show citation: Başkurt K, Uyar GC, Yeşilbaş E, et al. Limb Compression Therapy and Chemotherapy-Induced Peripheral Neuropathy in Women With Gynecologic Cancers: A Prospective Self-Controlled Study(NEURO-GLOVE Trial). Int J Cancer. 2026;159(9):2300-2313. doi:10.1002/ijc.70601
In the final episode of this nine-part series, Dr. Christine Cliatt-Brown discusses pharmacologic and non-pharmacologic management.